

HE7 Headache Review

Price: \$580.00

Register: (866) 611-5599 or www.AmericanSeminar.com

**Special Association accreditation may vary. See website.*

Women's Health/Neurology - Cynthia A. Stuenkel, MD and Megan Richie, MD

Assess risk for cardiovascular disease in women; Optimize risk management of cardiovascular disease in women; Identify risk factors for cognitive decline; Counsel patients with multiple sclerosis about lifestyle changes that may affect disease severity; Determine whether imaging of the brain is appropriate for a patient presenting with headache.

QUALIFIES FOR PAIN MANAGEMENT PM

IM 68 - 04

Clinical Pharmacology - Scott A. Braunstein, MD, James F. Neuenschwander II, MD and Matthew Siket, MD

Explain the clinical effects of ketamine based on the dose and route of administration; Select patients in the emergency department who are likely to benefit from treatment with ketamine; Integrate the prescription of buprenorphine into the treatment of opioid withdrawal; Identify contraindications for use of buprenorphine for patients with opioid withdrawal; Develop strategies for management of patients with severe headache in the emergency department.

QUALIFIES FOR PAIN MANAGEMENT-PM180 AND CLINICAL PHARMACOLOGY-PM180

EM 38 - 03

Headache/Gastrointestinal Infections - Christopher B. Oakley, MD and Camille Sabella, MD

Implement a multitiered approach to the treatment of headaches in children; Prescribe appropriate preventive therapies for children experiencing frequent headaches; Recognize the etiology of gastrointestinal infections based on clinical features; Select appropriate tests for the diagnosis of gastrointestinal infections; Optimize treatment of gastrointestinal infections in children.

PD 67 - 18

New and Emerging Therapies for Migraine - Fred Freitag, DO

Distinguish among types of calcitonin gene-related peptide monoclonal antibodies; Determine which pharmacologic agents are most appropriate for managing acute migraine, other types of migraine, and episodic cluster headaches; Identify small-molecule agents that target and inhibit calcitonin gene-related peptide (CGRP) receptors for treatment of acute migraine attacks; Recommend agents that manage migraine headache attacks through interactions with other serotonergic receptors, such as those that target the 5-HT₇ receptors; Characterize emerging therapies for the prevention and management of migraine headaches.

QUALIFIES FOR PAIN MANAGEMENT

NE 12 - 13

Headache Treatment/Post-traumatic Headache and Post-concussive Symptoms - Alan Rapoport and Alan Finkel

Select treatment strategies for primary headache disorders; Compare indications and efficacy of medications targeting calcitonin gene-related peptide for primary headache disorders; Utilize neuromodulation therapies for management of migraine; Identify signs and symptoms of concussion that are often omitted from commonly used checklists; Develop treatment strategies for post-traumatic headache and post-concussion syndrome.

QUALIFIES FOR PAIN MANAGEMENT

NE 12 - 14

Concussion and Post-concussion Headache in Children and Adolescents / Headache and Migraine in Children - Shannon E. Babineau, MD and Jack Gladstein, MD

Develop management strategies for pediatric patients with concussion or post-traumatic headache; Manage patients at high risk for post-concussion syndrome and post-traumatic headache; Identify typical and atypical presentations of migraine in children; Perform a differential diagnosis of pediatric patients who present with headache; Evaluate patients with headache for worrisome signs and symptoms.

NE 12 - 20

HE7 Headache Review

Price: \$580.00

Register: (866) 611-5599 or www.AmericanSeminar.com

**Special Association accreditation may vary. See website.*

Migraine/Intractable Headache Disorders - Marc DiSabella, DO

Navigate treatment options for migraine in children; Differentiate between primary and secondary headache disorder; Select appropriate treatment regimens for children with migraine; Identify pathophysiologic factors that contribute to migraine and intractable headache disorders; Choose among various treatment options, such as cognitive behavioral therapy, stimulatory devices, and pharmacologic treatment, for management of migraine and intractable headache.

PD 67 - 43

Headache/COVID-19 - Deborah I. Friedman, MD

Identify risk factors for idiopathic intracranial hypertension and spontaneous intracranial hypotension; Perform a diagnostic workup for idiopathic intracranial hypertension and spontaneous intracranial hypotension; Treat headache symptoms associated with idiopathic intracranial hypertension and spontaneous intracranial hypotension; Differentiate idiopathic intracranial hypertension and spontaneous intracranial hypotension from other headache etiologies; Develop strategies for modifying clinical workflow in ophthalmology practices to minimize risk for COVID-19 infection while maximizing quality of patient care.

OP 59 - 23

Migraine/Medication Overuse Headache - Jessica Ailani, MD and Mark W. Green, MD

Summarize the clinical efficacy and safety of novel therapies for migraine; Develop treatment strategies for migraine based on patient comorbidities, migraine characteristics, and response to prior therapy; Identify patients at high risk for medication overuse headache; Minimize risk for medication overuse headache among patients being treated for migraine; Appropriately use drugs that are preventative against migraine in patients with medication overuse headache.

NE 12 - 23

Autism in Adult Neurology/Migraine - Audrey Foster-Barber, MD and Stewart J. Tepper, MD

Assess data on proposed causes of ASD and the increase in its prevalence; Distinguish among syndromic disorders associated with ASD; Treat neurologic comorbidities of ASD; Choose an appropriate medication for the treatment of familial migraine syndromes; Explain the mechanism of action of monoclonal antibodies used in the treatment of migraine.

NE 13 - 02